Laboratory Software Market worth $10.62 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the laboratory software market to grow from USD 6.46 billion in 2026 to USD 10.62 billion by 2031, a 10.5% CAGR; AI-enabled software is forecast to grow fastest, at a 19.3% CAGR. North America held 39.4% of the global market in 2025, while services held 39.1%; implementation, integration, validation and training costs may constrain adoption. The report also describes 2025–2026 acquisitions and investment activity aimed at expanding laboratory informatics, AI and automation capabilities.

Analysis

This is a directional TAM estimate, not an earnings catalyst: a vendor-sponsored-style market forecast does not establish customer budgets, realized AI pricing, or public-company revenue capture. The investable mechanism is less “AI growth” than switching friction. Validation, instrument integration, and audit-trail requirements favor vendors already embedded in regulated workflows, while the services-heavy deployment mix is also evidence that adoption remains costly and slow. That can support implementation revenue but delay recurring-software conversion and limit near-term margin leverage.

Thermo Fisher (TMO), Agilent (A), and Waters (WAT) may benefit from bundling informatics with instruments and existing customer relationships, but software is only one part of diversified businesses; do not translate market CAGR directly into EPS. Revvity (RVTY) has a more specific optionality angle from ACD/Labs, though value depends on retention, integration, and cross-selling—not deal headlines. Dassault Systèmes (DSY) and Siemens (SIE) have broader software exposure, making this a diluted read-through. STARLIMS’ acquisition of MODA may strengthen its regulated manufacturing workflow offering; the article provides no basis to quantify either competitive impact or the effect on Lonza (LONN), which sold that platform.

Near term, expect little fundamental repricing from this report. Over 1–3 months, watch vendor disclosures for software growth, cloud mix, services capacity, and acquired-product cross-sell. Over 6–18 months, AI could improve workflow automation, but data quality, validation obligations, and customer security reviews may constrain deployment. The contrarian point: the fastest-growing AI subsegment may be small and hard to monetize, while implementation complexity—not total addressable market—sets the pace. Falsify the constructive thesis if vendors report slowing informatics bookings, weak renewals, or no measurable software attach despite AI launches.

Key Decisions for Investors

• No trade on the market forecast alone; treat the immediate signal as low-conviction and avoid extrapolating the projected sector growth rate into company earnings.
• Put RVTY on a conditional long watchlist, not an automatic buy: require evidence in upcoming disclosures of ACD/Labs customer retention, cross-selling, or informatics growth. Reassess if integration costs or weak uptake dilute the expected strategic benefit.
• Prefer monitoring TMO, A, and WAT for software attach and informatics bookings rather than buying them as pure-play beneficiaries; their diversified revenue bases make the read-through indirect.
• Track implementation lead times, services capacity, cloud migration, and renewal metrics over the next 1–3 months. Persistent deployment delays or weak renewals would undermine the adoption thesis even if AI interest remains high.